| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5569652 | BAYER HLTHCARE | Dihydrospirorenone as an antiandrogen |
Oct, 2013
(10 years ago) | |
| USRE37838 | BAYER HLTHCARE | Composition for contraception |
Jun, 2014
(9 years ago) | |
| USRE38253 | BAYER HLTHCARE | Composition for contraception |
Jun, 2014
(9 years ago) | |
| USRE37564 | BAYER HLTHCARE | Composition for contraception |
Jun, 2014
(9 years ago) | |
| USRE43916 | BAYER HLTHCARE | Composition for contraception |
Jun, 2014
(9 years ago) | |
| US5798338 | BAYER HLTHCARE | Solid dosage forms that contain clathrates of 17α-ethinyl estradiol |
Jul, 2015
(8 years ago) | |
| US6933395 | BAYER HLTHCARE | PROCESSING FOR PRODUCING OF DROSPIRENONE (6β, 7β, 15β, 16β-DIMETHYLENE-3-OXO-17α-PREGN-4-EN-21, 17-CARBOLACTONE, DRSP) AS WELL AS 7α-(3-HYDOXY-1-PROPLY)-6β, 7β; 15β, 16β-DIMETHYLENE-5β-ANDROSTANE-3β, 5,17β-TRIOL(ZK 92836) AND 6β, 7β; 15β, 16β-DIMETHYLENE-5β-HYDROXY |
Aug, 2017
(6 years ago) | |
| US6987101 | BAYER HLTHCARE | Therapeutic gestagens for the treatment of premenstrual dysphoric disorder |
Dec, 2017
(6 years ago) | |
| US6787531 | BAYER HLTHCARE | Pharmaceutical composition for use as a contraceptive |
Aug, 2020
(3 years ago) | |
| US6958326 | BAYER HLTHCARE | Cyclodextrin-drospirenone inclusion complexes |
Dec, 2021
(2 years ago) | |
| US7163931 | BAYER HLTHCARE | Compositions of estrogen-cyclodextrin complexes |
Dec, 2021
(2 years ago) | |
Yaz is owned by Bayer Hlthcare.
Yaz contains Drospirenone; Ethinyl Estradiol.
Yaz has a total of 11 drug patents out of which 11 drug patents have expired.
Expired drug patents of Yaz are:
- US5569652
- USRE37838
- USRE38253
- USRE37564
- USRE43916
- US5798338
- US6933395
- US6987101
- US6787531
- US6958326
- US7163931
Yaz was authorised for market use on 16 March, 2006.
Yaz is available in tablet;oral dosage forms.
Yaz can be used as prevention of pregnancy, treatment of symptoms of premenstrual dysphoric disorder, method of inducing contraception in a female of reproductive age who has not yet reached premenopause.
The generics of Yaz are possible to be released after 20 December, 2021.
Drugs and Companies using DROSPIRENONE; ETHINYL ESTRADIOL ingredient
Market Authorisation Date: 16 March, 2006
Treatment: Prevention of pregnancy; Method of inducing contraception in a female of reproductive age who has not yet reached premenopause; Treatment of symptoms of premenstrual dysphoric disorder
Dosage: TABLET;ORAL
YAZ family patents
